MAP855

MAP855 is a highly potent, selective, ATP-competitive and orally active MEK1/2 kinase inhibitor (MEK1 ERK2 cascade IC 50 =3 nM, pERK EC 50 =5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2 In Vitro MAP855 (compound 30) has single-digit nM inhibition of pERK and proliferation in A375 cells (pERK EC 50 =5 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay Cell Line: A375 cellsConcentration: 0-10 nM Incubation Time: 72 hours Result: Showed single-digit nM inhibition of pERK and proliferation in A375 cells (pERK EC 50 =5 nM). In Vivo MAP855 (3 mg/kg for i.v., 10 mg/kg for p.o.; single) has good oral bioavailability and medium clearance in rodents . MAP855 (30 mg/kg; p.o., b.i.d, 14 days) achieves comparable efficacy to trametinib dosed at the mouse MTD without any body weight loss . Pharmacokinetic Parameters of MAP855 in mouse, rat and dog . mouse rat dog CL [mL/min*kg] 32 35 22 V ss [l/kg] 2.6 2.0 1.8 AUC po d.n. [μM*h] 0.4 0.6 1.4 Oral BAV [% F ] 44 65 100 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Wistar Rats Dosage: 3 mg/kg for i.v., 10 mg/kg for p.o. Administration: i.v. and p.o., single Result: Showed good oral bioavailability and medium clearance. Animal Model: A375 Tumor Bearing Mice Dosage: 30 mg/kg Administration: p.o., b.i.d, 14 days Result: Achieved comparable efficacy to trametinib dosed at the mouse MTD without any body weight loss. Form:Solid IC50& Target:ERK 5 nM (EC 50 ) MEK1 3 nM (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet